相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Safety Run-In and Randomized Phase 2 Study of Cilengitide Combined With Chemoradiation for Newly Diagnosed Glioblastoma (NABTT 0306)
L. Burt Nabors et al.
CANCER (2012)
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
The Role of Integrins in Glioma Biology and Anti-Glioma Therapies
Ghazaleh Tabatabai et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Advances in malignant glioma drug discovery
David A. Reardon et al.
EXPERT OPINION ON DRUG DISCOVERY (2011)
Tumor angiogenesis: molecular pathways and therapeutic targets
Sara M. Weis et al.
NATURE MEDICINE (2011)
Treatment of high-grade glioma in children and adolescents
T. J. MacDonald et al.
NEURO-ONCOLOGY (2011)
Cilengitide induces autophagy-mediated cell death in glioma cells
Stephanie L. Lomonaco et al.
NEURO-ONCOLOGY (2011)
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group
Kenneth J. Cohen et al.
NEURO-ONCOLOGY (2011)
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
Kathryn Beal et al.
RADIATION ONCOLOGY (2011)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeting integrins in malignant glioma
Ghazaleh Tabatabai et al.
TARGETED ONCOLOGY (2010)
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
Tom Mikkelsen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro
Gabriele D. Maurer et al.
NEURO-ONCOLOGY (2009)
The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells
Gian Carlo Alghisi et al.
PLOS ONE (2009)
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme
David A. Reardon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study PBTC-012
Tobey J. MacDonald et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
L. B. Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
L. Burt Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice
Shinya Yamada et al.
NEUROSURGERY (2006)
O6-Methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas:: Results from the CCG-945 cohort
Ian F. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
FALM Eskens et al.
EUROPEAN JOURNAL OF CANCER (2003)
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha v integrin antagonist
TJ MacDonald et al.
NEUROSURGERY (2001)
分享论文
